Compare COLL & TY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COLL | TY |
|---|---|---|
| Founded | 2002 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2015 | N/A |
| Metric | COLL | TY |
|---|---|---|
| Price | $45.38 | $33.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $51.17 | N/A |
| AVG Volume (30 Days) | ★ 512.5K | 43.0K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.36% |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.63 | ★ 4.78 |
| Revenue | ★ $757,067,000.00 | N/A |
| Revenue This Year | $26.17 | N/A |
| Revenue Next Year | $3.65 | N/A |
| P/E Ratio | $28.19 | ★ $6.38 |
| Revenue Growth | ★ 26.34 | N/A |
| 52 Week Low | $23.23 | $25.16 |
| 52 Week High | $50.79 | $30.73 |
| Indicator | COLL | TY |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 54.76 |
| Support Level | $44.43 | $32.53 |
| Resistance Level | $48.29 | $33.54 |
| Average True Range (ATR) | 2.15 | 0.28 |
| MACD | -0.25 | 0.07 |
| Stochastic Oscillator | 31.27 | 81.68 |
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Tri-Continental Corp is a United States-based closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.